Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

773 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.
Cortellini A, Ricciuti B, Vaz VR, Soldato D, Alessi JV, Dall'Olio FG, Banna GL, Muthuramalingam S, Chan S, Majem M, Piedra A, Lamberti G, Andrini E, Addeo A, Friedlaender A, Facchinetti F, Gorría T, Mezquita L, Hoton D, Valerie L, Nana FA, Artingstall J, Comins C, Di Maio M, Caglio A, Cave J, McKenzie H, Newsom-Davis T, Evans JS, Tiseo M, D'Alessio A, Fulgenzi CAM, Besse B, Awad MM, Pinato DJ. Cortellini A, et al. Among authors: facchinetti f. J Immunother Cancer. 2022 Feb;10(2):e004374. doi: 10.1136/jitc-2021-004374. J Immunother Cancer. 2022. PMID: 35173031 Free PMC article.
Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M. Gelsomino F, et al. Among authors: facchinetti f. Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Crit Rev Oncol Hematol. 2014. PMID: 24355409 Review.
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F. Landi L, et al. Among authors: facchinetti f. Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16. Clin Lung Cancer. 2014. PMID: 25242668 Free article.
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.
Facchinetti F, Marabelle A, Rossi G, Soria JC, Besse B, Tiseo M. Facchinetti F, et al. J Thorac Oncol. 2016 Nov;11(11):1819-1836. doi: 10.1016/j.jtho.2016.05.027. Epub 2016 Jun 8. J Thorac Oncol. 2016. PMID: 27288978 Free article. Review.
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L. Facchinetti F, et al. Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. doi: 10.1158/1078-0432.CCR-16-0917. Epub 2016 Jul 11. Clin Cancer Res. 2016. PMID: 27401242 Clinical Trial.
773 results